Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04049448
Other study ID # ABX464-302
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 24, 2019
Est. completion date January 23, 2023

Study information

Verified date January 2023
Source Abivax S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as maintenance therapy in patients with moderate to severe rheumatoid arthritis.


Description:

This Phase 2a open-label study aims at investigating the long-term safety and efficacy of an oral dose of ABX464 in patients who have been previously enrolled in the ABX464-301 clinical study and who are willing to continue their treatment. All patients will receive ABX464 given at 50mg o.d. irrespectively of their previous treatment received in the ABX464-301 study (i.e. ABX464 or Placebo). The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation and also based on investigator's judgement. Patients will be treated with ABX464 for a period of 52 weeks. If they achieve a clinical response on Week 52 (defined as DAS28-CRP ≤ 2,6 for anti-TNFα naïve patients or DAS-28-CRP ≤ 3,2 for patients previously treated by anti-TNFα), they will be eligible to continue treatment for up to 104 weeks.Patients will be followed up at week , week 2 and then, on a monthly basis the first year (up to W52), and quaterly the second year (up to W104).


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 23, 2023
Est. primary completion date April 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 76 Years
Eligibility Inclusion Criteria: - Patients previously enrolled in the ABX464-301 clinical study who have completed the initial 12 weeks of treatment period; Criteria that should be met by patients at week 52 to be eligible for 52 additional weeks of study treatment: ? Patients should be in clinical response. Clinical response is defined as: DAS28-CRP = 2,6 for anti-TNFa naïve patients or DAS-28-CRP = 3,2 for patients previously treated by anti-TNFa. Exclusion Criteria: - Any condition, which in the opinion of the investigator, could compromise the patient's safety or adherence to the study protocol

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ABX464
All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 2 years (104 weeks).

Locations

Country Name City State
Belgium Cliniques Universitaires Saint-Luc Bruxelles
Belgium UZ Gent Gent
Belgium UZ Leuven Leuven
Belgium ZNA Jan Palfijn Merksem
Czechia Fakultni Tomayerova nemocnice Praha
Czechia Revmatologicky ustav Praha
France CHU de Brest - Hôpital Cavale Blanche Brest
France CHD Vendée La Roche-sur-Yon
France CHU DE MONTPELLIER - Hôpital Lapeyronie Montpellier
France GHR Mulhouse Sud-Alsace Mulhouse
France CHU de Nice - Hôpital Pasteur Nice
France CHR d'Orléans Orléans
France APHP - Hôpital Salpétrière Paris
France CHU de Tours - Hôpital Trousseau Tours
Hungary Complex Medical Centre - Déli Klinika Budapest
Hungary CRU Hungary Ltd. Miskolc
Hungary CMed Rehabilitációs és Diagnosztikai Központ Székesfehérvár
Poland ClinicMed Daniluk, Nowak Sp. J. Bialystok
Poland Pratia MCM Kraków
Poland Zespól Poradni Specjalistycznych REUMED Lublin
Poland NZOZ Lecznica MAK-MED S.C. Nadarzyn
Poland Medyczne Centrum Hetmanska Poznan
Poland National Institute of Geriatrics Warszawa
Poland RHEUMA MEDICUS Zaklad Opieki Zdrowotnej Warszawa

Sponsors (1)

Lead Sponsor Collaborator
Abivax S.A.

Countries where clinical trial is conducted

Belgium,  Czechia,  France,  Hungary,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment-emergent adverse events in the ABX464 treated Patients, categorized by severity Incidence of adverse events emerging during the treatment through study completion (average of 104 weeks)
Secondary Proportion of patients achieving Low Disease Activity (LDA) Low Disease Activity (LDA) is defined as DAS28-ESR <=3.2 Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Secondary Proportion of patients achieving American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission The ACR/EULAR boolean-based remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All = 1 Week 4, Week 12, Week24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Secondary Proportion of patients achieving Simplified Disease Activity Score (SDAI) remission The SDAI remission is considered achieved if the SDAI score = 3.3 Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Secondary Proportion of patients achieving Clinical Disease Activity (CDAI) remission The CDAI remission is considered achieved if the CDAI score = 2.8 Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Secondary Proportion of patients achieving ACR20/50/70 response The categorical American College of Rheumatology 20% or 50% or 70% (ACR20/50/70) response is a validated index of rheumatoid arthritis disease activity, defined by the number of patients who achieved at least 20% or 50% or 70% improvement in the ACR response. Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Secondary Proportion of patients achieving categorical Disease Activity Scores (DAS) (measured on 28 joints) - C-Reactive Protein (DAS28-CRP) response Proportion of patients achieving categorical Disease Activity Score (DAS) DAS28-C-Reactive Protein (CRP) [DAS28-CRP] response will be measured as moderate/good European League Against Rheumatism (EULAR) response Week 4, Week 12, Week 24, Week36, Week 52, Week 65, Week 78, Week 91 and Week 104
Secondary Time to onset of the Low Disease Activity (LDA) remission time when DAS28-ESR <=3.2 up to 104 weeks
Secondary Time to onset of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission The ACR/EULAR remission is a validated criteria based on: Tender/painful Joint Count (28), Swollen Joint Count (28), C-Reactive Protein, patient global assessment of disease, All = 1.
Time to onset will be when this criteria will be = 1
up to 104 weeks
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4